Table 4.
TSH | Free thyroxine (FT4) | Free triiodothyronine (FT3) | |||||||
---|---|---|---|---|---|---|---|---|---|
Before | Change | % Change | Before | Change | % Change | Before | Change | % Change | |
Caraccio et al. (23) | |||||||||
T4 | – | – | – | 11.6 | 2.8 | 24 | 4.8 | 0.3 | 6 |
Placebo | – | – | – | 12.7 | 0.2 | 2 | 4.8 | 0.1 | 2 |
Monzani et al. (30) | |||||||||
T4 | – | – | – | 11.3 | 2.6 | 23 | 4.8 | 0.1 | 2 |
Placebo | – | – | – | 10.9 | −0.1 | −1 | 4.6 | 0 | 0 |
Teixeira et al. (27) | |||||||||
T4 | 8.0 | −5.88 | −74 | 12.9 | 4.1 | 32 | – | – | – |
Placebo | 8.4 | −3.5 | −42 | 12.9 | 2 | 16 | – | – | – |
Teixeira et al. (28) | |||||||||
T4 | 7.5 | −4.6 | −61 | 14.2 | 0 | 0 | – | – | – |
Placebo | 8.01 | −2.01 | −25 | 14.2 | 1.2 | 8 | – | – | – |
Nagasaki et al. (32) | |||||||||
T4 | 7.32 | −4.62 | −63 | 14.5 | 1.5 | 10 | 5.06 | 0.08 | 2 |
Placebo | 7.25 | −0.24 | −3 | 14 | 0.8 | 6 | 4.92 | 0.2 | 4 |
Total cholesterol | LDL cholesterol | HDL cholesterol | |||||||
Before | Change | % Change | Before | Change | % Change | Before | Change | % Change | |
Caraccio et al. (23) | |||||||||
T4 | 5.5 | −0.5 | −9 | 3.6 | −0.5 | −14 | 1.5 | −0.1 | −7 |
Placebo | 5.3 | 0 | 0 | 3.3 | 0.1 | 3 | 1.5 | 0 | 0 |
Monzani et al. (30) | |||||||||
T4 | 5.54 | −0.58 | −10 | 3.59 | −0.51 | −14 | 1.46 | −0.05 | −3 |
Placebo | 5.51 | 0.17 | 3 | 3.55 | 0.1 | 3 | 1.47 | 0.02 | 1 |
Teixeira et al. (27) | |||||||||
T4 | 5.62 | −0.52 | −9 | 3.57 | −0.51 | −14 | 1.36 | 0.06 | 4 |
Placebo | 4.83 | 0.41 | 8 | 2.94 | 0.41 | 14 | 1.43 | −0.18 | −13 |
Teixeira et al. (28) | |||||||||
T4 | 5.54 | −0.58 | −10 | 3.57 | −0.48 | −13 | 1.44 | −0.08 | −6 |
Placebo | 4.87 | 0.19 | 4 | 3.05 | 0.38 | 12 | 1.43 | −0.14 | −10 |
Nagasaki et al. (32) | |||||||||
T4 | 5.59 | −0.4 | −7 | 3.58 | −0.44 | −12 | 1.41 | 0 | 0 |
Placebo | 5.53 | −0.2 | −4 | 3.56 | −0.2 | −6 | 1.38 | 0.01 | 1 |
Triglycerides | Apolipoprotein A | Apolipoprotein B | |||||||
Before | Change | % Change | Before | Change | % Change | Before | Change | % Change | |
Caraccio et al. (23) | |||||||||
T4 | 1.3 | −0.1 | −8 | 1.618 | −0.128 | −8 | 1.096 | −0.083 | −8 |
Placebo | 1.4 | −0.1 | −7 | 1.584 | 0.031 | 2 | 1.053 | 0.018 | 2 |
Monzani et al. (30) | |||||||||
T4 | 1.06 | −0.07 | −7 | 1.66 | −0.14 | −8 | 1.07 | −0.09 | −8 |
Placebo | 1.07 | 0.09 | 8 | 1.65 | 0.04 | 2 | 1.17 | 0.01 | 1 |
Teixeira et al. (27) | |||||||||
T4 | 1.21 | −0.02 | −2 | 1.376 | 0.04 | 3 | 0.966 | 0.059 | 6 |
Placebo | 1.08 | 0.31 | 29 | 1.338 | −0.034 | −3 | 0.915 | 0.009 | 1 |
Teixeira et al. (28) | |||||||||
T4 | 1.16 | −0.07 | −6 | 1.403 | 0.093 | 7 | 0.948 | −0.041 | −4 |
Placebo | 1.11 | −0.1 | −9 | 1.407 | 0.019 | 1 | 0.889 | 0.017 | 2 |
Nagasaki et al. (32) | |||||||||
T4 | 1.34 | 0.16 | 12 | – | – | − | – | – | – |
Placebo | 1.37 | 0.01 | 1 | – | – | – | – | – | – |